Eikonizo Therapeutics is developing oral, brain-penetrant, highly selective small molecule histone deacetylase 6 (HDAC6) inhibitors as disease-modifying therapeutics for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease (PD) and Alzheimer’s disease (AD)
Eikonizo Therapeutics is developing oral, brain-penetrant, highly selective small molecule histone deacetylase 6 (HDAC6) inhibitors as disease-modifying therapeutics for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease (PD) and Alzheimer’s disease (AD).